Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 6/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.32 |
| ▸ | HTR3B | O95264 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.32 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.32 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.31 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9242468 | 0.85 | KIF11 (0.39) | KIF11TDP1KDRERN1 | |
| SCHEMBL7272536 | 0.84 | TDP1 (0.42) | KIF11TDP1KDRERN1NOTUM | |
| SCHEMBL12725572 | 0.84 | KIF11 (0.47) | KIF11ERN1 | |
| SCHEMBL9342742 | 0.80 | TDP1 (0.42) | KIF11TDP1KDRERN1NOTUM | |
| SCHEMBL679217 | 0.79 | ERN1 (0.44) | TDP1KDRERN1PDK1HTR3E | |
| SCHEMBL1808858 | 0.79 | TDP1 (0.48) | TDP1ERN1 | |
| SCHEMBL1965867 | 0.79 | TDP1 (0.43) | TDP1ERN1 | |
| SCHEMBL677944 | 0.78 | KIF11 (0.40) | KIF11TDP1KDRERN1 | |
| SCHEMBL9340536 | 0.78 | KIF11 (0.46) | KIF11ERN1 | |
| SCHEMBL3620779 | 0.78 | TDP1 (0.39) | KIF11TDP1KDRERN1PDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0396987-B1 | Nuclear fluorinated trifluoromethylbenzaldehydes | BAYER AG (DE) | 1994-06-15 | — | — | EP | claimed |
| EP-0396987-A2 | Nuclear fluorinated trifluoromethylbenzaldehydes | BAYER AG (DE) | 1990-11-14 | — | — | EP | claimed |
| EP-3006443-B1 | BENZOTHIOPHENE COMPOUND | ASTELLAS PHARMA INC (JP) | 2018-04-25 | — | — | EP | disclosed |
| US-9399038-B2 | Benzothiophene compound | ASTELLAS PHARMA INC. (JP) | 2016-07-26 | — | — | US | disclosed |
| US-9399038-B2 | Benzothiophene compound | ASTELLAS PHARMA INC. (JP) | 2016-07-26 | — | — | US | disclosed |
| US-9399038-B2 | Benzothiophene compound | ASTELLAS PHARMA INC. (JP) | 2016-07-26 | — | — | US | disclosed |
| EP-3006443-A1 | BENZOTHIOPHENE COMPOUND | Astellas Pharma Inc. (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-20150133433-A1 | BENZOTHIOPHENE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-05-14 | — | — | US | disclosed |
| US-20150133433-A1 | BENZOTHIOPHENE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-05-14 | — | — | US | disclosed |
| US-20150133433-A1 | BENZOTHIOPHENE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-05-14 | — | — | US | disclosed |
| US-8981119-B2 | Benzothiophene compound | ASTELLAS PHARMA INC. (JP) | 2015-03-17 | — | — | US | disclosed |
| US-8981119-B2 | Benzothiophene compound | ASTELLAS PHARMA INC. (JP) | 2015-03-17 | — | — | US | disclosed |
| US-8981119-B2 | Benzothiophene compound | ASTELLAS PHARMA INC. (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20140364421-A1 | BENZOTHIOPHENE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-20140364421-A1 | BENZOTHIOPHENE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-20140364421-A1 | BENZOTHIOPHENE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| EP-0396987-B1 | Nuclear fluorinated trifluoromethylbenzaldehydes | BAYER AG (DE) | 1994-06-15 | — | — | EP | disclosed |
| US-5041683-A | Nuclear-fluorinated trifluoromethylbenzaldehydes | BAYER AKTIENGESELLSCHAFT (DE) | 1991-08-20 | — | — | US | disclosed |
| EP-0396987-A2 | Nuclear fluorinated trifluoromethylbenzaldehydes | BAYER AG (DE) | 1990-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133433-A1 | BENZOTHIOPHENE COMPOUND | TRPA1, TRPV1, TRPV3 | KIF11 3944/4885TDP1 1234/4885KDR 3828/4885 |
| US-20140364421-A1 | BENZOTHIOPHENE COMPOUND | TRPA1, TRPV1, TRPV4 | KIF11 3148/4885TDP1 653/4885KDR 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.